Clinical Trial Update: Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating extended-duration low-dose apixaban to prevent recurrent venous thromboembolism in high-risk patients with provoked VTE; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Status: COMPLETED | Results posted: 2025-09-30